29.03.2023 SARTORIUS AG  DE0007165607

EQS-News: SARTORIUS AG: Alexandra Gatzemeyer joins Executive Board of Sartorius to lead the Lab Products & Services division


EQS-News: SARTORIUS AG / Key word(s): Personnel
SARTORIUS AG: Alexandra Gatzemeyer joins Executive Board of Sartorius to lead the Lab Products & Services division

29.03.2023 / 19:50 CET/CEST
The issuer is solely responsible for the content of this announcement.

Göttingen, March 29, 2023

Alexandra Gatzemeyer joins Executive Board of Sartorius to lead the Lab Products & Services division

At today’s meeting, the Supervisory Board of Sartorius AG appointed Alexandra Gatzemeyer, Ph.D., as Member of the Executive Board, effective May 1, 2023. From June 16, 2023, Alexandra Gatzemeyer will succeed Gerry Mackay, Board Member and Head of the Lab Products & Services division, who will hand over duties in the course of May and June to ensure a smooth transition at the helm of this division. After stepping down as Executive Board member as of June 16, 2023, Gerry Mackay will continue to support Sartorius in various cross-divisional tasks and initiatives.

Alexandra Gatzemeyer currently leads the LPS Sales & Services organization at Sartorius. During her more than 18 years tenure with the company, she served in various senior leadership roles including Product Management, Human Resources Management, and as Managing Director of a country organization. Alexandra holds a Ph.D. in pharmaceutical chemistry and pharmacology from the St. Petersburg State Chemical and Pharmaceutical University.

Dr. Lothar Kappich, Chairman of the Supervisory Board of Sartorius AG, thanked Gerry Mackay and welcomed Alexandra Gatzemeyer on behalf of the Board. „Our lab business has evolved tremendously under Gerry Mackay’s leadership. During the past four years he has executed the strategic repositioning of the division towards the life science market, integrated more than a handful of acquisitions, substantially advanced its sales and marketing capabilities while boosting profitability. When extending his contract in 2021, Gerry had already signaled to be available for two more years only,” said Lothar Kappich. “At the same time, we would like to warmly welcome Alexandra, an internationally experienced and successful manager from our own ranks, to join the Executive Board. Backed by her passion for customers and people Alexandra will further push the division’s strategic and operational path towards becoming a leading partner for innovative solutions for life science research.“

From June 16, 2023, the Sartorius Executive Board will thus consist of the four following members:
Dr. Joachim Kreuzburg, Chairman and CEO; Dr. René Fáber, Head of Bioprocess Solutions; Alexandra Gatzemeyer, Head of Lab Products & Services; and Rainer Lehmann, Chief Financial Officer.

This press release contains forward-looking statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no liability for updating such statements in light of new information or future events. This is a translation of the original German-language release. Sartorius shall not assume any liability for the correctness of this translation. The original German release is the legally binding version.

A profile of Sartorius
The Sartorius Group is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications and vaccines safely, rapidly and economically. The company based in Goettingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius delivers significant organic growth and regularly expands its portfolio through the acquisition of complementary technologies. In fiscal 2022, the company generated sales revenue of around 4.2 billion euros. At the end of 2022, around 16,000 employees were working for customers around the globe.

Petra Kirchhoff
Head of Corporate Communications & Investor Relations
+49 (0)551 308 1686
[email protected]

Follow Sartorius on Twitter and LinkedIn.

29.03.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language: English
Otto-Brenner-Straße 20
37079 Göttingen
Phone: +49.(0)551-308.0
Fax: +49.(0)551-308.3289
E-mail: [email protected]
Internet: www.sartorius.com
ISIN: DE0007165607, DE0007165631
WKN: 716560 , 716563
Indices: DAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1596247

End of News EQS News Service

1596247  29.03.2023 CET/CEST


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 1.404,57 1.566,03 1.826,97 2.335,66 3.449,22 4.174,70 3.395,70
EBITDA1,2 353,20 405,00 495,80 636,70 1.134,26 1.410,40 962,70
EBITDA-Marge3 25,15 25,86 27,14 27,26 32,89 33,78
EBIT1,4 219,36 298,61 335,66 456,11 903,16 1.070,00 503,90
EBIT-Marge5 15,62 19,07 18,37 19,53 26,18 25,63 14,84
Jahresüberschuss1 159,33 197,48 218,74 299,56 426,98 655,40 290,00
Netto-Marge6 11,34 12,61 11,97 12,83 12,38 15,70 8,54
Cashflow1,7 206,51 244,52 377,19 511,53 865,81 734,20 853,60
Ergebnis je Aktie8 2,11 2,56 3,06 4,37 8,08 9,57 4,94
Dividende8 0,51 0,61 0,35 0,70 1,25 1,43 0,45
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: -

Sartorius ST
WKN Kurs in € Einschätzung Börsenwert in Mio. €
716560 275,500 Halten 23.482,37
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
45,16 39,18 1,15 63,35
10,23 24,17 6,92 26,55
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
1,43 0,73 0,26 28.03.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
18.04.2024 19.07.2024 17.10.2024 16.02.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
5,43% 6,92% 3,96% -13,91%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu SARTORIUS AG  ISIN: DE0007165607 können Sie bei EQS abrufen

Medtech , 716560 , SRT , XETR:SRT